Ozempic Off-Label Prescribing Causes Supply Shortages

The use of semaglutide for off-label purposes, such as weight loss rather than diabetes, is causing supply shortages in Germany. The boom in semaglutide prescriptions in Germany began in 2022, driven by users seeking to exploit side effects like weight loss. Production is finally catching up with demand for the weight loss injection in the medical market. German health insurance providers currently only cover the costs of semaglutide for patients with diabetes. Global helium supply and pricing are expected to take a long time to return to normal levels. Qatar, the world's largest helium producer, has suspended its production. This shortage impacts the semiconductor industry, as chips require helium for manufacturing. A shortage of helium is moving into a second phase characterized by uncertainty regarding product availability. The situation is described as a transition from price increases to doubts about whether supplies will be available at all. This practice aims to exploit the medication's side effect of weight reduction. The resulting high demand and hype have led to supply shortages, according to a physician. The trend is occurring even before the market availability of other medications like Wegovy and Mounjaro.